The 80 references in paper I. Bobkova N., M. Shestakova V., A. Schukina A., И. Бобкова Н., М. Шестакова В., А. Щукина А. (2015) “Диабетическая нефропатия - фокус на повреждение подоцитов // Diabetic nephropathy - focus on podocytes damage” / spz:neicon:nefr:y:2015:i:2:p:33-44

1
Дедов ИИ. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция). Сахарный диабет 2010; 3: 6-12 [Dedov II. Saharny`i` diabet: razvitie tekhnologii` v diagnostike, lechenii i profilaktike (plenarnaia lektciia). Saharny`i` diabet 2010; 3: 6-12]
(check this in PDF content)
2
Шамхалова МШ, Трубицына НП, Шестакова МВ. Новые перспективы терапии пациентов с сахарным диабетом 2 типа. Сахарный диабет 2012; 4: 109-114 [Shamhalova MSh, Trubitcy`na NP, Shestakova MV. Novy`e perspektivy` terapii patcientov s saharny`m diabetom 2 tipa. Saharny`i` diabet 2012; 4: 109-114
(check this in PDF content)
3
Лебедева НО, Викулова ОК. Маркеры доклинической диагностики диабетической нефропатии у пациентов с сахарным диабетом 1 типа. Сахарный диабет 2012; 2: 38-45 [Lebedeva NO, Vikulova OK. Markery` doclinicheskoi` diagnostiki diabeticheskoi` nefropatii u patcientov s saharny`m diabetom 1 tipa. Saharny`i` diabet 2012; 2: 38-45]
(check this in PDF content)
4
International Diabetes Federation. Diabetes Atlas. Sixth edition; 2013
(check this in PDF content)
5
Дедов ИИ, Шестакова МВ. Сахарный диабет и хроническая болезнь почек. Медицинское информационное агентство, М., 2009 [Dedov II, Shestakova MV. Saharny`i` diabet i khronicheskaia bolezn` pochek. Meditcinskoe informatcionnoe agentstvo, M., 2009]
(check this in PDF content)
6
Шестакова МВ, Шамхалова МШ, Ярек-Мартынова ИЯ и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет 2011; 1: 81-88 [6. Shestakova MV, Shamhalova MSh, Iarek-Marty`nova IIA i dr. Saharny`i` diabet i khronicheskaia bolezn` pochek: dostizheniia, nereshenny`e problemy` i perspektivy` lecheniia. Saharny`i` diabet 2011; 1: 81-88]
(check this in PDF content)
7
Granier C, Makni K, Molina L et al. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 7922-8799
(check this in PDF content)
8
Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49:1399-1408
(check this in PDF content)
9
Shankland SJ. Podocyte′s response to injury: role in proteinuria and sclerosis. Kidney Int 2006; 69:2131-2147
(check this in PDF content)
10
Kimmelstiel P, Wilson C. Intercapillary lesion in the glomeruli of the kidney. Am J Pathol 1936; 12: 82-97
(check this in PDF content)
11
Stitt-Cavanagh E, MacLeod L, Kennedy CRJ. The podocyte in diabetic kidney disease. The Scientific World Journal 2009; 9:1127-1139
(check this in PDF content)
12
Reddy GR, Kotlyarevska K, Ransom RF. The podocyte and diabetes mellitus: is the podocyte key to the origins of diabetic nephropathy? Сurr Opin Nephrol Hypertens 2008; 17: 32-36
(check this in PDF content)
13
Wolf G, Chen S, Ziyadeh FN. From the periphery of glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54(6): 1626-1634
(check this in PDF content)
14
Ziyadeh FN, Wolf G. Pathogenesis of podocytopathy and proteiuria in diabetic glomerulopathy. Current Diabetes Reviews 2008; 4: 39-45
(check this in PDF content)
15
Steffes MW, Schmidt D, McGregory R, Basgen JM. Glomerular cell number in normal subject and in type 1diabetic patients. Kidney Int 2001; 59: 2104-2113
(check this in PDF content)
16
Pätäri A, Forsblom C, Havana M et al. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003; 52: 2969-2974
(check this in PDF content)
17
Lewko B, Stepinski J. Hypergliycemia and mechanical stress: Targeting the renal podocyte. J Cell Physiol 2009; 221(2): 288-295
(check this in PDF content)
18
Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis 2011; 58(4): 637-646
(check this in PDF content)
19
Vestra MD, Masiero A, Roiter AM et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52:1031-1035
(check this in PDF content)
20
Nakatsue T, Koike H, Han GD et al. Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. Kidney Int 2005; 67: 2239-2253
(check this in PDF content)
21
Huh W, Kim DJ, Kim M-K et al. Expression of nephrin in acquired human glomerular disease. Nephrol Dial Transplant 2002; 17: 478-484
(check this in PDF content)
22
Ng DPK, Tai BC, Tan E et al. Nephrinuria associates with multiple renal traits in type 2 diabetes. Nephrol Dial Transplant. 2010; 26: 2508-2514.
(check this in PDF content)
23
Jim B, Ghanta M, Qipo A et al. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross Sectional study. PLoS ONE 2012; 7(5): e36041
(check this in PDF content)
24
Doublier S, Salvidio G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy of type 1 diabetes. Diabetes 2003; 52: 2969-2974
(check this in PDF content)
25
Koop K, Eikhmans M, Baelde HJ et al. Expression of podocyte-associated molecules in acquired human kidney diseases. Am J Soc Nephrol 2003; 14: 2063-2071
(check this in PDF content)
26
Benigni A, Gagliardini E, Tomasoni S et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65: 2193-2200
(check this in PDF content)
27
Chen HC, Chen CA, Guh JY et al. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 2000; 67:2345-2353
(check this in PDF content)
28
Regoli M, Bendayan M. Alteration in the expression of alpha3beta1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 1997; 40: 15-22
(check this in PDF content)
29
Nakamura T, Ushiyama C, Suzuki S et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15:1379-1383
(check this in PDF content)
30
Wogelmann SU, Nelson WJ, Myers BD et al. Urinary excretion of podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285: F40-F48
(check this in PDF content)
31
Sanches-Nino MD, Sanz AB, Sanches-Lopes E et al. HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. Laboratory Investigation 2012; 92: 32-45
(check this in PDF content)
32
Susztac K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 226-233
(check this in PDF content)
33
Versola D, Gandolfo MT, Ferrario F et al. Apoptosis in the kidney of the patients with type 2 diabetic nephropathy. Intern Soc Nephrol. 2007; 72: 1262-1272.
(check this in PDF content)
34
Liu Y. New insights into epithelial-mesenchymal transitition contribute in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222
(check this in PDF content)
35
Wolf G, Wenzel U, Ziadeh FN et al. Angiotensin convertingenzyme inhibitor treatment reduces glomerular p16 INK4 and p27Kip1 expression in diabetic BBdp rats. Diabetologia 1999; 42: 11425-11432
(check this in PDF content)
36
Griffin SV, Peterman AN, Durvasula RV et al. Podocyte proliferation and differentiation in glomerular disease: role of cell-cycle regulatory proteins. Nephrol Dial Transplant 2003; 18(6): 8-13
(check this in PDF content)
37
Xu ZG, Yoo TH, Ryu DR et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose stimulated podocytes and in diabetic glomeruli. Kidney Intern 2005; 67: 944-952
(check this in PDF content)
38
Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35
(check this in PDF content)
39
Kriz W, Le Hir M. Pathway to nephron loss starting from glomerular diseases-insights from animal models. Kidney Intern 2005; 67:404-419
(check this in PDF content)
40
Wiggins RC: The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int 2007; 71: 1205–1214
(check this in PDF content)
41
Steffes MW, Schmidt D, Mc Grery R et al. Glomerular cell number in normal subjects and in type 1diabetic patients. Kidney Intern 2001; 59: 2104-2113
(check this in PDF content)
42
Meyer TW, Bennett PH, Nelson RG et al. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999; 42:1341-1344
(check this in PDF content)
43
White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in 2 type diabetic patients. Nephrol Dial Transplant 2004; 9:1437-1440
(check this in PDF content)
44
Abbate M, Zoja C, Morigi M et al. Transforming growth factor-beta 1 is upregulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161: 21792193
(check this in PDF content)
45
Durvasula RV, Petermann AT, Hiromura K et al. Activation of local tissue angiotensin system in podocytes by mechanical strain. Kidney Intern 2004; 65: 309
(check this in PDF content)
46
Ichihara A, Kaneshiro Y, Takemuro T et al. The (pro)renin receptor and the kidney. Sem Nephrol 2007; 27: 524-528
(check this in PDF content)
47
Parving HH, Persson P, Lewis EJ et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Eng J Med 2008; 358:2433-2446
(check this in PDF content)
48
Ding G, Reddy K, Kapasi AA et al. Angiotensin II induces apoptosis in rat glomerularepithelial cells. Am J Physiol Renal Physio. 2002; 283: F173-180
(check this in PDF content)
49
Schiffer M, Mundel P, Shaw AS et al. A novel role for the adapter molecule CD2-associated protein in transforming growth factor-beta-1-induced apoptosis. J Biol Chem 2004; 279: 3700437012
(check this in PDF content)
50
Mifsud SA, Allen TJ, Bertram JF et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-882
(check this in PDF content)
51
Gross ML, El-Shakmak A, Szabo A et al. ACE-inhibitor but not endothelin receptor blockers prevent podocyte loss in early nephropathy. Diabetologia 2003; 46: 856-868
(check this in PDF content)
52
Flannery PJ, Spurney RF. Transactivation of epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephrol Exp Nephrol 2006; 103: e109-1018
(check this in PDF content)
53
Yard BA, Kahlert S, Engelleiter R et al. Decreased glomerular expression of agrin in diabetic nephropathy and podocytes, culturedin high dglucose medium. Exp Nephrol 2001; 9: 214-222
(check this in PDF content)
54
Chen S, Lee JS, Iglesias-de la Cruz MC et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005; 20: 1320–1328
(check this in PDF content)
55
Wolf G. Free radical production and angiotensin. Curr Hypertens Rep. 2000; 2:167-173.
(check this in PDF content)
56
Kritz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Intern 2005; 67: 404-419
(check this in PDF content)
57
Böttinger EP. TGF-beta in renal injury and disease. Semin Nephrol 2007; 27(3):309-320
(check this in PDF content)
58
Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis buildup. Sem Nephrol 2003; 23:532-543
(check this in PDF content)
59
Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB Journal 2004; 18 (7): 816-827
(check this in PDF content)
60
Li Y, Kang YS, Dai C et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172: 299-308
(check this in PDF content)
61
Yamaguchi Y, Iwano M, Suzuki D et al. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009; 54(4): 653–664
(check this in PDF content)
62
Tufro А. VEGF and podocytes in diabetic nephropathy. Sem Nephrol 2012; 32 (4): 385-393
(check this in PDF content)
63
Veron D, Bertuccio CA, Marlier A et al. Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 2011; 54: 1227-1241
(check this in PDF content)
64
Kim NH, Kim KB, Kim DL et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabet Med 2004; 21: 545-551
(check this in PDF content)
65
Fan Q, Xing Y, Ding J, Guan N. Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats. Nephron Exp Nephrol 2009; 111: e92
(check this in PDF content)
66
Foster RR, Saleem MA, Mathieson PW et al. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocyte. Am J Physiol Renal Physiol 2005; 288: F48-57
(check this in PDF content)
67
Nakamura T, Ushiyama C, Osada S et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50:1193–1196
(check this in PDF content)
68
Zhang Y, Guan Y. PPAR-gamma agonists and diabetic nephropathy. Curr Diab Rep 2005; 5: 470–475
(check this in PDF content)
69
Benigni A, Zoja C, Tomasoni S et al. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006; 17: 1624–1632
(check this in PDF content)
70
Lennon R, Welsh GI, Singh A. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 2009; 52: 1944–1952
(check this in PDF content)
71
Zhang H, Saha J, Byun J et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: F1071–F1081
(check this in PDF content)
72
Крячкова АА, Савельева СА, Галлямов МГ и др. Роль ожирения в поражении почек при метаболическом синдроме. Нефрология и диализ 2010 12(1): 34-38 [Kriachkova AA, Savel`eva SA, Galliamov MG i dr. Rol` ozhireniia v porazhenii pochek pri metabolicheskom sindrome. Nefrologiia i dializ 2010 12(1): 34-38]
(check this in PDF content)
73
Савельева СА, Крячкова АА, Курумова КО и др. Ожирение – фактор риска поражения почек у больных сахарным диабетом 2 типа. Сахарный диабет 2010; 2: 45-50 [ Savel`eva SA, Kriachkova AA, Kurumova KO i dr. Ozhirenie – faktor riska porazheniia pochek u bol`ny`kh saharny`m diabetom 2 tipa. Saharny`i` diabet 2010; 2: 45-50]
(check this in PDF content)
74
Сагинова ЕА, Северова ММ, Галлямов МГ и др. Клиническое значение адипонектинемии в формировании поражения органов-мишеней при метаболическом синдроме, ассоциированном с неалкогольной жировой болезнью печени. Сеченовский вестн 2011; 1-3: 18-25 [Saginova EA, Severova MM, Galliamov MG i dr. Clinicheskoe znachenie adiponektinemii v formirovanii porazheniia organov-mishenei` pri metabolicheskom sindrome, assotciirovannom s nealkogol`noi` zhirovoi` bolezn`iu pecheni. Sechenovskii` vestneyk 2011; 1-3: 18-25]
(check this in PDF content)
75
Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645–1656
(check this in PDF content)
76
Lee MH, Song HK, Ko GJ et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008; 74: 890–900
(check this in PDF content)
77
Lenz O, Fornoni A. Renin-angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center. Kidney Int 2008; 74: 851–853
(check this in PDF content)
78
Harvey SJ, Jarad G, Cunningham J et al. Podocytespecific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 2008; 19: 2150–2158
(check this in PDF content)
79
Ho J, Ng KH, Rosen S et al. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 2008; 19: 2069-2065
(check this in PDF content)
80
Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Nat Acad Sci USA 2007; 104: 3432–3437 Авторы заявляют об отсутствии конфликта
(check this in PDF content)